These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34405613)

  • 1. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
    Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
    [No Abstract]   [Full Text] [Related]  

  • 2. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
    Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
    Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
    Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A
    J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Histopathological features of squamous cell carcinoma of lung neoadjuvant immunotherapy focusing on responses].
    Wei JC; Yuan P; Ling Y; Li L; Guo CY; Guo L; Xue LY; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):453-457. PubMed ID: 33915650
    [No Abstract]   [Full Text] [Related]  

  • 5. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
    Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
    Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
    Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
    Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of intestinal obstruction stent combined with neoadjuvant chemotherapy on the pathological characteristics of surgical specimens in patients with complete obstructive colorectal cancer].
    Cao K; Diao XL; Yu JF; Li GB; Zhai ZW; Zhao BC; Wang ZJ; Han JG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Nov; 25(11):1012-1019. PubMed ID: 36396377
    [No Abstract]   [Full Text] [Related]  

  • 8. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
    Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
    [No Abstract]   [Full Text] [Related]  

  • 9. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
    Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
    Front Immunol; 2022; 13():938269. PubMed ID: 36059450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.
    Liu-Jarin X; Stoopler MB; Raftopoulos H; Ginsburg M; Gorenstein L; Borczuk AC
    Mod Pathol; 2003 Nov; 16(11):1102-8. PubMed ID: 14614049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
    Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
    J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
    Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
    Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status of postoperative pathological diagnosis of lung cancer in China: a multicenter big data study].
    ;
    Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):882-890. PubMed ID: 34344071
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
    Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
    J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
    Poettgen C; Theegarten D; Eberhardt W; Levegruen S; Gauler T; Krbek T; Stamatis G; Teschler H; Kuehl H; Bockisch A; Stuschke M
    Oncology; 2007; 73(5-6):316-23. PubMed ID: 18497503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
    Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
    Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
    Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
    Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.